The pharmaceutical company AstraZeneca registered the official name of its Covid vaccine, which will become Vaxzevria. The European Medicines Agency (Ema) approved and communicated it. Naming a customary new drug. The vaccine didn’t have a name and now it does, the company explained.
The new AstraZeneca package insert
also released the new package insert of the vaccine where, among the side effects, they are mentioned the very rare cases of cerebral venous thrombosis observed in young women (under 55 and not recorded in the older population). The EMA has not ruled out or established a link between these cases and the vaccine and will publish an update at the next meeting of its safety committee, to be held from 6 to 9 April, a meeting that will help clarify how often the reported adverse effect occurs and whether the risk may vary based on age or gender .
Germany recommends its use only for people over 60
For these reasons,
yesterday the commission on vaccines in Germany has decided to recommend AstraZeneca for people over 60 years old only. Germany investigates a total of 31 cases of rare blood clots in the brain, 9 of which resulted in death in previously vaccinated people. So far, most of the reports have come from women under 65, but there could be due to the type of population vaccinated: many countries used AstraZeneca initially on people under 65 e groups such as health workers and teachers, the majority of which are women.
Rare thrombosis and the possible explanation
On the subject, he arrives
one study led by German coagulation specialist Andreas Greinacher, of the University of Greifswald, who may have found an explanation for the rare thrombosis and, perhaps, a way to prevent and deal with them. The team of researchers found that this very unusual combination of symptoms (widespread blood clots and, at the same time, a low platelet count) resembles an equally rare side effect of the heparin blood thinner called heparin-induced thrombocytopenia (Hit). Identifying similarities and course can help prevent and, if so, a treat the manifestations of adverse reactions. Hit can occur in some people who, after taking heparin, produce antibodies against the binding that the drug initiates with a protein called platelet factor 4 (PF4), a reaction that causes uncontrolled clotting. Greinacher and the other scientists thought that something similar could happen in the case of the rare thrombosis, but without heparin.
No evidence of a link between thrombosis and vaccine
Despite these remarks,
the link between the vaccine and any unproven Hit, nor is it explained how the drug could favor its onset, but doctors could benefit from this information. When recognized in time, in fact, Hit can be treated with immunoglobulins and some blood thinners (without heparin) which can help dissolve clots.
March 31, 2021 (change March 31, 2021 | 11:07 am)